Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrelizumab combined with GC regimen for advanced bladder cancer
ChiCTR2100041865Phase 4Recruiting
- Sponsor
- Baotou Cancer Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, gemcitabine and cisplatin in bladder cancer and transitional cell carcinoma (TCC), sponsored by Baotou Cancer Hospital. Primary endpoint: Objective response rate. Started Feb 2021; status: recruiting.
02
Drugs
camrelizumabgemcitabinecisplatin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2100041865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041865.